GermanyGermany

Wilex finds US commercialisation partner for Rencarex

03.05.2011

Munich/San Diego – German Wilex has sold the exclusive US marketing rights for RENCAREX® (girentuximab), its Phase III monoclonal antibody for adjuvant use in non-metastatic clear-cell renal cell cancer (ccRCC) to Prometheus Laboratories Inc. Under the terms of the agreement, Wilex will receive $19.0 million upfront, development fees, plus milestone payments and royalties on U.S. net sales of the chimeric monoclonal antibody that targets the CA IX-antigen, which is overexpressed on 95% of ccRCC and various other solid tumours. Additionally, Wilex has options for commercialisation outside the United States to one of Prometheus' marketed products or additional cash payments of up to $20 million. With the deal, the US company, which has a track record of commercialisation of oncology products, strengthens its oncology pipeline. girentuximab is currently being tested in a Phase III trial versus placebo in the adjuvant setting in 864 patients with non-metastatic clear cell renal cell cancer at high risk of recurrence after nephrectomy. WILEX expects the results from the interim analysis for efficacy of girentuximab in the second half of 2011, which could form the basis for the European MAA.

GermanyGermany

01.04.2011

Saarbruecken – For a decade, stem cell researchers have tried to unravel how epi­gentic reprogramming works at the molecular level. Now, German researchers have discovered how the epigenetic code in the paternal part of the...

GermanyGermany

28.03.2011

Cologne – Insulin resistance represents a key process in the development of diabetes II, which has reached epidemic proportions in industrial nations. Researchers from TaconicArtemis Pharmaceuticals and from the University of...

GermanyGermany

01.03.2011

Martinsried-based Scil Technology has named its former CFO Christian Nafe as new Managing Director of the company. Nafe takes over from Dr. Weishui Weiser, who retires after five years at this post. It is the second time Nafe...

GermanyGermany

10.02.2011

Hamburg-based Evotec AG is to expand its drug discovery capacity with a EUR12m acquisition. Yesterday, the company announced the purchase of private chemical proteomics specialist Kinaxo Biotechnologies GmbH. The transaction,...

GermanyGermany

06.02.2011

Munich – For the first time, researchers have provided evidence that mRNAs can be used as drugs. By repairing genetic defects in knock-out mice, a team under Carsten Rudoph from Ludwig-Maximilians University in Munich...

GermanyGermany

06.02.2011

Berlin – German bioengineers have grown the world’s first hair follicle from autologous stem cells in vitro. Lead investigator Roland Lauster (TU Berlin) said the discovery will speed up research on the causes of baldness, but...

GermanyGermany

06.02.2011

Berlin – In the second major biotech-related funding project from the German Federal Ministry of Education and Research (BMBF) within two months, the ministry announced that Germany will be spending more than EUR5.5bn on a...

GermanyGermany

06.02.2011

Munich – MorphoSys AG had a busy end of the year, announcing the achievement of clinical milestones four, five, six and seven from previous collaborations and a new cooperation agreement with Pfizer. This is a direct result of...

GermanyGermany

27.01.2011

Berlin – German researchers have identified a completely new target for blood pressure regulation in the liver of mice. In yesterday’s issue of Neuron (69 (2) pp. 332-344) the team headed by Friedrich Luft (MDC Berlin) and...

GermanyGermany

21.01.2011

Hamburg – Evotec AG has entered into a collaboration with Takeda Cambridge Limited, to identify small molecule modulators against GPCR and protease targets involved in CNS and metabolic diseases. Under the terms of the agreement,...

Displaying results 51 to 60 out of 454

< Previous 51-60 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-germany/browse/5/article/wilex-finds-us-commercialisation-partner-for-rencarex.html

Events

All Events

Stock list

All quotes

TOP

  • 4SC1.17 EUR0.00%
  • ACTELION109.60 CHF0.00%
  • ADDEX3.10 CHF0.00%

FLOP

  • CYTOTOOLS31.45 EUR-0.47%
  • 4SC1.17 EUR0.00%
  • ACTELION109.60 CHF0.00%

TOP

  • CO.DON3.32 EUR32.8%
  • PAION3.05 EUR26.6%
  • EPIGENOMICS3.83 EUR23.2%

FLOP

  • ADDEX3.10 CHF-23.8%
  • EVOTEC3.08 EUR-15.8%
  • MEDIGENE3.93 EUR-14.6%

TOP

  • SANTHERA88.05 CHF2058.1%
  • CO.DON3.32 EUR286.0%
  • PAION3.05 EUR202.0%

FLOP

  • CYTOS0.24 CHF-94.0%
  • BIOFRONTERA2.20 EUR-39.7%
  • MERCK KGAA68.48 EUR-39.7%

No liability assumed, Date: 19.09.2014


Current issue

All issues

Product of the week

Products